Processa pharmaceuticals provides interim analysis from ongoing phase 1b trial of next generation capecitabine showing improved safety over capecitabine

Fda acknowledges that ngc-cap is a new chemical entity given the changes to metabolism and distribution of its major metabolite 5-fu
PCSA Ratings Summary
PCSA Quant Ranking